Leflunomide
- Generic Name
- Leflunomide
- Brand Names
- Arava, Leflunomide medac, Leflunomide Zentiva (previously Leflunomide Winthrop), Leflunomide ratiopharm
- Drug Type
- Small Molecule
- Chemical Formula
- C12H9F3N2O2
- CAS Number
- 75706-12-6
- Unique Ingredient Identifier
- G162GK9U4W
- Background
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
- Indication
For the management of the signs and symptoms of active rheumatoid arthritis (RA) to improve physical function and to slow the progression of structural damage associated with the disease. Has also been used for the prevention of acute and chronic rejection in recipients of solid organ trasnplants and is designated by the FDA as an orphan drug for this use.
- Associated Conditions
- Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis
- Associated Therapies
- -
Effect of Leflunomide on T Cell Proliferation in HIV-Infected Patients
- Conditions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 41
- Registration Number
- NCT00101374
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
- Conditions
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00003775
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer
- Conditions
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00004071
- Locations
- 🇺🇸
St. Vincents Comprehensive Cancer Center, New York, New York, United States
🇺🇸Comprehensive Cancer Care Specialists of Boca Raton, Boca Raton, Florida, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00003293
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Leflunomide to Treat Uveitis
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 16
- Registration Number
- NCT00001863
- Locations
- 🇺🇸
National Eye Institute (NEI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.